CRINETICS PHARMACEUTICALS INC. - COMMON STOCK

Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 8 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

08 8 2024 15:05:01 提供 Nasdaq GlobeNewswire

Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges

08 8 2024 07:30:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

18 7 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 7 2024 18:29:44 提供 Nasdaq GlobeNewswire

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner

18 6 2024 15:30:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 6 2024 17:35:30 提供 Nasdaq GlobeNewswire

Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)

03 6 2024 11:00:00 提供 Nasdaq GlobeNewswire

Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly

03 6 2024 11:00:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs

30 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts

22 5 2024 07:00:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 5 2024 16:38:21 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

09 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

08 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024

02 5 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 4 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

19 3 2024 05:00:00 提供 Nasdaq GlobeNewswire

Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome

12 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 3 2024 15:05:00 提供 Nasdaq GlobeNewswire

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

28 2 2024 15:05:00 提供 Nasdaq GlobeNewswire